MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed...
MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed...
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple...
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple...
On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE)...
Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology centerFort Mill, SC, Dec. 18, 2025 (GLOBE NEWSWIRE)...
On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE)...
Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology centerFort Mill, SC, Dec. 18, 2025 (GLOBE NEWSWIRE)...
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve...
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve...
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker...
Full-Year Revenues of $18.6 million and Net Loss of $2.2 millionMISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems...
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker...
Full-Year Revenues of $18.6 million and Net Loss of $2.2 millionMISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025...